SEURAT Affordability

The SEURAT platform has several cost advantages that its competitors do not. For example:

Minimal 3rd-Party License Costs

  • SEURAT has minimal reliance on 3rd-party visualization components.
    Other products rely heavily on incorporating 3rd-party visualization components that come with large licensing costs that get passed on to the customer.
  • SEURAT is developed with open-source tools and code libraries.
  • SEURAT Runs on What You Have

  • SEURAT does not assume that you have a Big Pharma IT infrastructure.
    The SEURAT software architecture avoids the need to buy expensive high-end hardware or software application servers.
  • The Seurat server only requires 256 megabytes of memory for a typical installation that supports 50 to 80 users.
  • SEURAT works easily with your database and we don't charge consulting fees to set it up.
  • SEURAT is written in Java and runs on Windows, Linux, Unix and Mac.
  • No Big Investment Costs to Recover

  • The cost to initially develop and test SEURAT is already paid by a different company when it was created for in-house use (see our history). Consequetly, this up-front investment cost is not passed on to you.
  • Pricing

    Contact us for the latest pricing information.

    There is a significant discount for academic users. And we are interested in partnering with universities to use SEURAT in research programs.

    Affordability

    Tired of paying Big Pharma prices for software tools? SEURAT is the Big Pharma tool at the small pharma price.
    Learn more »

    Scalability

    Have hundreds of users and multiple databases? SEURAT can handle it.
    Learn more »

    Interoperability

    Have home-grown or 3rd party tools? SEURAT can share data with them.
    Learn more »

    Easy to Config & Maintain

    Tired of overblown tools requiring a lot of your own IT staff to install, configure and maintain? SEURAT makes life easy.
    Learn more »

    Customers

    Two top 15 Pharma deployments. Over 1000 users accross both biotech and pharma.
    Learn more »

    Newsletter

    Nov 2009 »